BRAF and skin cancer: Notably, our results suggest connections between SOX10 and BRAF in the etiology of skin cancer and modulating their shared DDPs via chemotherapeutics might open a new avenue to rescue resistance to BRAF/MEK inhibitors in melanoma patients [28].